For schemes with a three-yearly funding valuation in 2024, life expectancy, and in particular how this might change in the future, will be a key assumption. A lot has changed in the last three years and reflecting current views on future life expectancy could save corporates millions.

It’s clear that current views of longevity will be a significant part of discussion at 2024 funding valuations and, from a corporate perspective, this will require careful consideration.

Understanding the profile of your membership, particularly with detailed analysis, and comparing the scheme to the broader UK and other real-world considerations is a helpful starting place in informing what an appropriate assumption could be.

To read our current views, click the button below.

READ MORE

For further information or support, please get in touch.